

Clinical Trials Navigator Report

Patient: ~~XXXXXXXXXX~~

Study 1:

Title: Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers

ID: NCT04092179

URL: <https://ClinicalTrials.gov/show/NCT04092179>

Eligibility Status: May be eligible. IDH2 mutated AML disease.

Phase: 1/2

Study Location(s):

- PMH
 - o Contact: Dr. Steven Chan (416-946-2253 or steven.chan@uhn.ca)

Study 2:

Title: Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

ID: NCT02719574

URL: <https://ClinicalTrials.gov/show/NCT02719574>

Eligibility Status: May be eligible.

Phase: 1/2

Study Location(s):

- PMH
 - o Contact: Deborah Sanfelice 416-946-4501 ext 2867

Study 3:

Title: Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS

ID: NCT03187288

URL: <https://ClinicalTrials.gov/show/NCT03187288>

Eligibility Status: May be eligible.

Phase: 1

Study Location(s):

- PMH
 - o Contact: Dr. Karen Yee (416-946-4495)

Study 4:

Title: Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

ID: NCT03541369

URL: <https://ClinicalTrials.gov/show/NCT03541369>

Eligibility Status: May be eligible.

Phase: 1

Study Location(s):

- PMH (No contact information posted)

Study 5:

Title: A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

ID: NCT02848001

URL: <https://ClinicalTrials.gov/show/NCT02848001>

Eligibility Status: May be eligible.

Phase: 1

Study Location(s):

- PMH (No contact information posted)
-

Study 6:

Title: A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

ID: NCT04336982

URL: <https://ClinicalTrials.gov/show/NCT04336982>

Eligibility Status: May be eligible.

Phase: 1/2

Study Location(s):

- PMH (Not Yet Recruiting)
 - o No Contact Information Posted
-